Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)

The registry lists NCT06719973 as withdrawn, last updated 2025-06-17. Enrolment is 0 actual participants. Interventions: M9466, Carboplatin, Etoposide, Atezolizumab, M9446. Primary measures include Module 1 and Module 2: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Treatment Related TEAEs; Module 1 and Module 2: Number of Participants with Dose-limiting Toxicity (DLT). The registry reason for stopping is: Study was terminated due to decision made not to proceed with the clinical trial DDRiver 521, that has not yet commenced enrolment, for strategic reasons. No results are posted in the registry; this does not exclude separate publications.